Effect of N-acetylcysteine ​​and glycine supplementation to improve glutathione levels

Abstract

Compositions are provided for various medical conditions associated with reduced glutathione levels. [Solution] A composition for treating an individual for one or more medical or physical conditions, comprising glycine or a functional derivative thereof and N-acetylcysteine, or a dipeptide of glycine and N-acetylcysteine, wherein the glycine derivative is selected from the group consisting of D-allylglycine, N-[bis(methylthio)methylene]glycine methyl ester, Boc-allyl-Gly-OH (dicyclohexylammonium) salt, Boc-D-Chg-OH, Boc-Chg-OH, etc., and mixtures thereof.

Description

[Technical field]

[0001]

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 167,433, filed May 28, 2015, the entire contents of which are incorporated herein by reference.

[0002]

[0002] This disclosure is directed to at least the fields of biochemistry, cell biology, chemistry, molecular biology, and medicine. [Background technology]

[0003]

[0003] The free radical theory of aging suggests that the biological process of aging results in increased oxidative stress in older individuals. The ability of cells to resist the potentially harmful effects of oxidative stress depends on the biological balance between the production of oxidant free radicals and the large number of protective antioxidants available to the cell. There are multiple antioxidant defense systems, of which glutathione (GSH) is the most abundant intracellular component of the overall antioxidant defense. GSH is a tripeptide that is synthesized from the precursor amino acids glutamate, cysteine, and glycine in two steps catalyzed by glutamate cysteine ​​ligase (GCL, also known as γ-glutamylcysteine ​​synthetase, EC 6.3.2.2) and γ-L-glutamyl-L-cysteine:glycine ligase (also known as glutathione synthetase, EC 6.3.2.3), whereas GSH synthesis occurs ab initio within the cell.

[0004] Glutathione deficiency has been implicated in several human diseases, including diabetes, HIV infection, protein-energy malnutrition in children, sickle cell anemia, infectious diseases, neurological disorders such as Parkinson's disease, liver disease, and cystic fibrosis. Evidence from several animal (Stohs et al., 1984; Farooqui et al., 1987; Liu et al., 2000) and human (Al-Turk et al., 1987; Matsubara et al., 1991; Lang et al., 1992; Samiec et al., 1998; Erden-Inal et al., 2002; Logercio et al., 1996) studies suggests that glutathione levels decline with aging. GSH deficiency in aging is associated with an increased shift towards prooxidative states (Rebrin, 2008) and leads to increased oxidative stress (Rikans and Hornbrook, 1997). These changes have been implicated in age-related diseases, such as cataracts (Campisi et al., 1999; Castorina et al., 1992; Sweeney et al., 1998), age-related macular degeneration (Samiec, 1998), altered immune function (Fidelus and Tsan, 1987; Furukawa et al., 1987) and neurodegenerative diseases (Liu et al., 2004), as well as increased DNA damage at the molecular level (Hashimoto et al., 2008). The pathogenesis of age-related glutathione deficiency is not fully understood, but it has been suggested that disturbances in glutathione synthesis may be involved (Toroser and Sohal, 2007).

[0005] Other and further objects, features, and advantages will become apparent from the following description of the presently preferred embodiments of the invention which have been set forth for purposes of disclosure. Summary of the Invention

[0006]

[0006] Embodiments of the present disclosure relate to methods and / or compositions for treating or preventing or delaying the onset of a medical or physical condition directly or indirectly associated with a decrease in intracellular GSH levels. Embodiments of the present disclosure also relate to methods and / or compositions for treating or preventing or delaying the onset of a medical or physical condition directly or indirectly associated with a decrease in blood or intracellular levels of cysteine ​​and / or glycine. In certain embodiments, the intracellular GSH level in an individual is increased when the medical or physical condition is treated, prevented, or delayed in onset. In certain embodiments, the C-reactive protein (CRP) level in an individual is decreased when the medical or physical condition is treated, prevented, or delayed in onset.

[0007]

[0007] In certain embodiments, the method is intended to provide benefits from glutathione, n-acetylcysteine ​​and / or glycine, and in certain cases, there is an individual and / or collective contribution of glutathione, n-acetylcysteine ​​and / or glycine.

[0008] In one embodiment of the disclosure, there is a method for providing elevated blood levels of cysteine ​​and glycine (e.g., cysteinylglycine) (or functional derivatives thereof) in an individual in need thereof to increase intracellular GSH levels. The individual may be known to have a medical or physical condition that may benefit from elevated GSH levels, or the individual may be suspected of having a medical or physical condition that may benefit from elevated GSH levels. In certain embodiments, the individual to whom the methods and / or compositions of the invention are administered desires to prevent one or more undesirable physical conditions (or the effects of a physical condition such as those associated with aging) or medical conditions. In certain embodiments, the individual is provided with effective levels of cysteine ​​and glycine or functional derivatives thereof for the express purpose of increasing GSH levels to treat, prevent, or delay the onset of a medical or physical condition.

[0009]

[0009] In certain embodiments, the individual is identified as one in need of treatment (or prevention or delay of onset) of a medical condition associated with insufficient GSH levels.

[0010]

[0010] The embodiments of the present disclosure relate to various methods for treating or preventing or delaying the onset of one or more medical or physical conditions associated with insufficient levels of glutathione in one or more cells of an individual. In certain embodiments, the methods are for treating or preventing or delaying the onset of one or more medical or physical conditions associated with insufficient concentrations of intracellular glycine and / or cysteine. In certain aspects, the methods allow for the treatment or prevention or delay of the onset of one or more medical or physical conditions due to the inherent effect of restoring intracellular concentrations of glycine and / or cysteine ​​independent of GSH. In certain embodiments, the condition or physical state comprises at least one of the following: muscle weakness (due to any reason, including at least sarcopenia, HIV infection, aging and / or cachexia, adverse effects of weightlessness); organ dysfunction (including, for example, diabetes and insulin resistance and diabetic nephropathy); cardiac function and failure (for example, prevention or amelioration of heart failure and / or improvement of cardiac systolic function); fatty liver; cancer prevention; fetal metabolic programming to prevent the later development of obesity and / or diabetes; maternal and fetal health in gestational diabetes; athletic performance and physical function; obesity; quality of life; longevity; neurodegenerative disease; individuals undergoing imaging tests or procedures, or prevention of acetaminophen toxicity in HIV-associated neuropathy. prophylaxis to prevent nephropathy in;non-alcoholic steatohepatitis;non-alcoholic fatty liver disease (with or without inflammation);tinnitus;dizziness;alcohol hangover;hearing loss;Alzheimer's disease;Parkinson's disease;osteoporosis, high blood pressure, atherosclerosis / coronary artery disease, and myocardial damage following stress such as burns or trauma;cystic fibrosis;hepatic fatty diseases non-alcoholic fatty liver disease;inflammation;improving memory and cognition;post-trauma recovery and survival (e.g. post-surgery, post-sepsis, post-blunt or penetrating trauma from an accident or physical assault, etc.);brain trauma (including concussion);improving recovery from general trauma and surgery;prevention of diabetes;treatment or prevention of pre-diabetes / metabolic syndrome, etc.

[0011] In one embodiment, there is a method for preventing and / or treating sarcopenia, sarcopenic obesity, or cachexia. In a particular embodiment for cachexia, cachexia is present in an individual due to an underlying medical condition (e.g., being chronically ill, having HIV, having cancer, having COPD, aging in an otherwise healthy individual (sarcopenia), etc.). In a particular embodiment for elderly HIV patients, supplementation with the compositions contemplated herein increases glutathione, resulting in increased lean mass (muscle) and decreased body fat mass.

[0012]

[0012] Certain embodiments of the present disclosure provide for the prevention and / or treatment of eye conditions that result directly or indirectly from low GSH levels, including low levels in the eye's lens (known to be rich in glutathione), such as cataracts and / or glaucoma, presbyopia (age-related loss of near vision, requiring reading glasses), or, for example, presbycusis (age-related hearing loss, requiring hearing aids).

[0013] In a particular embodiment, there is a method for the prevention and / or treatment of various types of inflammation, and in a particular embodiment, the method involves lowering C-reactive protein (CRP; an inflammation marker) or lowering TNF-α, such as in HIV patients. In a particular embodiment, the inflammation is associated with a response to a harmful stimulus, such as one or more pathogens, damaged cells, and / or irritants. The inflammation can be acute or chronic. In some cases, inflammation is associated with disorders such as aging, diabetes, acne, asthma, autoimmune diseases, celiac disease, prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, interstitial cystitis, atherosclerosis, allergies, muscle diseases, white blood cell abnormalities, drug reactions (such as cocaine or ecstasy), cancer, depression, and muscle repair. It is recognized that inflammation is immune-related, and in a particular embodiment, there is a method of providing NAC and glycine to an individual receiving a vaccine to enhance the immune response to the vaccine.

[0014] In certain embodiments, the disclosed methods prevent and alleviate / treat mitochondrial toxicity, such as drug-induced mitochondrial toxicity. For example, an individual with HIV and undergoing antiretroviral HIV medication that is detrimental to mitochondrial function is provided with an effective amount of NAC and glycine to improve mitochondrial function.

[0015]

[0015] In a particular embodiment, there is a method for preventing and / or treating acetaminophen toxicity. In particular, an individual who takes acetaminophen, or is taking acetaminophen, or has acetaminophen toxicity is provided with an effective level of one or more compositions as contemplated herein. An individual who has acetaminophen toxicity may or may not be a chronic user of acetaminophen. In a particular embodiment, an individual takes acetaminophen simultaneously with taking one or more agents that increase GSH levels in the individual.

[0016] In certain embodiments, there is a method for improving muscle activity and recovery, such as from muscle stress (including muscle stress associated with exercise). In certain embodiments, the individual is an athlete, but the individual may not be an athlete. The individual may be engaged in recreational and / or health-related exercise. The individual may take one or more agents that increase GSH levels in the individual before, during, and / or after exercise (including before and / or after exercise, and within minutes, hours, or days before and / or after exercise). The individual may take one or more agents that increase intracellular levels of cysteine ​​and / or glycine in the individual before, during, and / or after exercise (including before and / or after exercise, and within minutes, hours, or days before and / or after exercise). In certain embodiments, increasing intracellular NAC and / or glycine increases muscle activity and / or recovery, independent of its effect on GSH. Exercise can be of various kinds, for example, aerobic ("cardio") exercise and / or weight training. The individual may have a medical or physical condition that is directly or indirectly related to reduced GSH levels. In certain embodiments, the individual is an elderly individual with HIV, for example, an individual aged 50 years or older. Studies have shown that elderly HIV patients who took a composition as contemplated herein experienced a significant increase in muscle strength in both hands within two weeks.

[0017]

[0017] Embodiments of the present disclosure include methods for treating, preventing, or delaying the onset of accelerated aging in non-elderly individuals, where accelerated aging may be due to any reason, including at least HIV infection or exposure to weightlessness for any period of time. In certain embodiments, there is reversal of accelerated aging (such as seen in the presence of HIV, weightlessness, or age-related deficiencies (decreased function, reduced muscle strength, reduced quality of life, formation of cataracts, immunosenescence), as seen typically in non-HIV humans (approximately 70-80 years of age) at a much earlier age (50 years or younger) in HIV-infected patients). In a particular embodiment, there is a method of extending lifespan in an individual. In certain embodiments, the individual is at least 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 years of age. In certain embodiments of the present disclosure, lifespan is extended in an individual provided with an effective amount of glycine and n-acetylcysteine. Thus, in certain embodiments of the present invention, there are methods and compositions related to extending lifespan in an individual. The individual may or may not have a life-threatening medical condition. In the case of weightlessness, for example, muscle atrophy and / or osteopenia may be present, as may individuals who experience weightlessness.

[0018] In certain embodiments, there is an improvement in cognitive function in an individual, including for individuals with no detectable impairment in cognitive function, or for individuals with detectable impairment in cognitive function, including impairment for any reason. In certain embodiments, the method delays the onset of cognitive impairment or enhances normal cognitive function. Cognitive function can be defined as the mental process of knowing, including aspects such as sensing, perceiving, reasoning, and judging, including but not limited to, becoming known through perception, reasoning, or intuition, knowledge. In certain embodiments, a composition as contemplated herein is provided to an individual to improve memory, including in the case of normal or memory-impaired individuals.

[0019]

[0019] Embodiments of the present disclosure include methods of ameliorating skeletal muscle loss that occurs for any reason, including cachexia, sarcopenia, inactivity, and stress (including post-surgery, sepsis, and post-trauma), etc. The amelioration can be a reduction in the rate or amount of muscle loss and / or reversal of muscle loss.

[0020] In one embodiment, there is a prophylaxis to prevent or treat nephropathy, at least in individuals undergoing, for example, imaging examinations or procedures, or individuals with diabetes and / or HIV. Nephropathy can be damage to or disease of the kidney, and nephropathy can be non-inflammatory or inflammatory. Examples of nephropathy include glomerular deposition of IgA antibodies, administration of analgesics, xanthine oxidase deficiency, toxicity of chemotherapy or other drugs, long-term exposure to lead or its salts; systemic lupus erythematosus, trauma, post-obstructive uropathy, nephritis; nephrotic syndrome; diabetes mellitus and high blood pressure (hypertension), which lead to diabetic nephropathy and hypertensive nephropathy.

[0021] In certain embodiments, the present invention relates to compositions and methods related to the use of glycine and n-acetylcysteine ​​(NAC) for therapeutic and / or prophylactic applications in mammals in need thereof. The mammals may be of various kinds, including, for example, humans, dogs, cats, horses, pigs, sheep, and goats. In certain embodiments, the present invention is directed to one or more methods and / or compositions related to impaired glutathione turnover and / or elevated oxidative stress and / or oxidative damage in mammals, including impaired glutathione turnover and / or elevated oxidative stress and / or oxidative damage in aging or diabetes. In certain embodiments, the present invention relates to the beneficial effects of foods (including at least dietary supplements) having glycine and n-acetylcysteine ​​in mammals in need thereof, including, for example, those that are aging or have diabetes.

[0022]

[0022] Mammals in need thereof can include those in need of prevention or treatment of the deleterious effects of aging, in need of prevention or treatment of diabetes or diabetic complications, or in need of prevention or treatment of one or more of the following dyslipidemias: insulin resistance, obesity, fatty acid oxidation, diabetic dyslipidemia, diabetic microvascular complications (e.g., nephropathy, retinopathy, and / or neuropathy), high cholesterol and / or triglyceride levels, fatty liver disease, neurodegenerative diseases in aging, statin-induced myopathy.

[0023] In some embodiments, the present invention relates to individuals (e.g., elderly individuals) who have reduced GSH levels for any reason, including reduced synthesis and, in certain embodiments, reduced synthesis due to insufficient availability of precursor amino acids. A low GSH state predisposes the individual to increased oxidative stress (e.g., as measured by plasma markers of oxidative damage). Supplementation with both NAC and glycine results in improved GSH synthesis and concentrations and reduced plasma markers of damage, and in certain embodiments, the functional derivative aspects of NAC and glycine are particularly effective. Improvements in GSH through increased synthesis can have an impact on at least metabolic health, including metabolism of mitochondrial energy sources, insulin resistance, body composition, and muscle strength. This can be achieved by increasing the availability of the precursors cysteine ​​and glycine by administration in various forms and precursors, including at least N-acetylcysteine ​​(NAC), L-glycine, L-glycine ethyl ester, and dipeptide forms (e.g., cysteinylglycine or n-acetylcysteinylglycine). In certain embodiments, supplementation with NAC and / or glycine results in improvements to at least metabolic health (including mitochondrial energy metabolism, insulin resistance, body composition and muscle strength) that occur independently of GSH.

[0024] In one embodiment of the present invention, there are methods and compositions useful for reducing and / or preventing oxidative stress in an individual. In a particular embodiment, the methods and compositions are useful for treating and / or preventing a medical condition associated with oxidative stress. In a particular embodiment, the methods and compositions of the present invention are useful for treating and / or preventing a medical condition associated with reduced glutathione levels. In a particular embodiment of the present invention, the methods and compositions are useful for treating diabetes. In a particular aspect of the present invention, the methods and compositions are useful for providing to the elderly. In certain instances, the present invention provides methods and compositions useful for aging.

[0025]

[0025] In certain embodiments, the present invention relates to compositions and the following representative method(s): a method for reducing plasma F2-isoprostane levels, a method for reducing plasma F3-isoprostane and / or F2-isoprostane levels and / or neuroprostane and / or F4-isoprostane levels (e.g., as this method is associated with a marker for oxidative stress in the brain), a method for increasing GSH production, a method for increasing intracellular concentrations of GSH, a method for increasing GSH levels in the liver (or separately, e.g., in muscle), a method for improving insulin sensitivity, a method for increasing fat oxidation, a method for reducing body weight, a method for treating / preventing dyslipidemia, a method for treating / preventing fatty liver disease and / or reducing excess fat content in the liver, a method for reducing cholesterol levels, a method for preventing muscle disease (including statin-induced myopathy), and / or a method for reducing triglyceride levels.

[0026] In one embodiment of the invention, there is a composition consisting essentially of glycine and N-acetylcysteine. In another embodiment of the invention, there is a composition consisting essentially of glycine and n-acetylcysteine.

[0027] In certain embodiments, there is a method of increasing the production of GSH in an individual, comprising providing an effective amount of glycine and n-acetylcysteine ​​to the individual.

[0028]

[0028] In certain embodiments of the present disclosure, because aging is associated with impaired fat oxidation and obesity, and is also associated with glutathione deficiency due to impaired synthesis, provision of glycine and n-acetylcysteine ​​restores glutathione synthesis and concentrations and also improves fat oxidation, insulin resistance, obesity, and / or dyslipidemia.

[0029]

[0029] In certain embodiments, there are methods for preventing and / or treating hangovers due to alcohol consumption using compositions encompassed by the present disclosure. Hangovers may be caused, in certain embodiments, directly or indirectly by depletion of GSH stores or by the interaction of acetaldehyde with GSH and / or cysteine, resulting in their depletion. In some embodiments, hangovers are directly or indirectly caused by excess congeners, including many substances such as amines, acetone, acetaldehyde, histamine, and tannins, and those that are particularly toxic. Alcohol can be of various kinds, including spirits (dark or light), beer, and / or wine. In certain embodiments, restoration of healthy glutathione levels in cells protects against oxidative stress, counteracts the effects of acetaldehyde, and protects against or reduces the adverse effects of hangovers.

[0030]

[0030] In certain embodiments, there are methods for preventing and / or treating polycystic ovary syndrome (PCOS) in an individual using the compositions contemplated herein. In certain embodiments, the methods directly or indirectly address excess insulin (caused by any reason, which affects the ovaries by increasing the production of androgens, inhibiting the ovaries' ability to ovulate). In some embodiments, the methods for preventing and / or treating PCOS address low-grade inflammation (which stimulates the polycystic ovaries to produce androgens).

[0031] In certain embodiments, an effective amount of glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof is provided to an individual to enhance immunity after vaccination. In certain embodiments, in the absence of provision of glycine (or a functional derivative thereof) and N-acetylcysteine ​​(or a functional derivative thereof), vaccination elicits a lower level of immunity compared to provision of the vaccine when the individual is administered the composition. In certain embodiments, correcting glutathione with glycine / NAC increases the likelihood of successful vaccination, especially in populations where essential immune cell function is deficient (e.g., geriatric elderly and immunosenescent populations such as HIV-infected patients). Vaccine failure rates are typically higher in these populations, and in certain embodiments, glycine / NAC overcomes such deficiencies. In certain embodiments, an individual is given glycine / NAC before, simultaneously with, and / or after the vaccine. In certain embodiments, an individual takes glycine / NAC before the vaccine for a period of months, weeks, or days. In certain cases, the individual is administered glycine / NAC 1, 2, 3, or 4 weeks prior to the vaccine. In certain embodiments, the individual takes glycine / NAC on a monthly basis, weeks, or days after the vaccine. In certain embodiments, the individual is administered glycine / NAC 1, 2, 3, or 4 weeks after the vaccine. In certain embodiments, there are methods for treating hearing loss in an individual or preventing hearing loss in an individual susceptible to hearing loss by providing an effective amount of glycine and / or NAC (or functional derivatives thereof). In certain embodiments, the individual is susceptible to hearing loss, such as due to aging, loud noise, head trauma, infection, disease, genetic conditions, deformities, and combinations thereof. The hearing loss may be partial or complete, and one or both ears may be affected.

[0032] In certain embodiments, there is a method for treating brain trauma (TBI-TBI acute and chronic conditions) and / or concussion or preventing brain trauma (TBI-TBI acute and chronic conditions) and / or concussion in an individual in need thereof. The TBI or concussion may be the result of an accident, trauma, and the like. In certain embodiments of the method, an effective amount of glycine and / or NAC (or functional derivatives thereof) is provided to the individual prior to and / or after the onset of the TBI and / or concussion.

[0033] In certain embodiments, ototoxicity (e.g., due to drugs (e.g., antibiotics, aminoglycosides, loop diuretics, platinum-based chemotherapy agents (such as cisplatin), nonsteroidal anti-inflammatory drugs)), tinnitus, vertigo, dizziness, and / or Meniere's disease are treated or prevented in an individual by providing an effective amount of glycine and / or NAC (or a functional derivative thereof). The condition may be reversible and temporary, or irreversible and permanent, in the absence of glycine and / or NAC (or a functional derivative thereof).

[0034] In certain embodiments, the compositions of the present disclosure are beneficial to lipid metabolism in the liver. The effect can be attributed to glutathione, n-acetylcysteine, and / or glycine, and in certain embodiments, to the individual and / or collective contributions of each of these components.

[0035] In embodiments of the present disclosure, the methods and / or compositions are utilized in any mammal, including humans, horses, dogs, cats, goats, sheep, cattle, pigs, and the like.

[0036]

[0036] In one embodiment, there is a method of treating an individual for one or more medical or physical conditions comprising providing to the individual an effective amount of a composition comprising glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof, the medical or physical condition being selected from the group consisting of: (a) muscle weakness, (b) adverse effects of weightlessness, (c) organ damage, (d) cardiac function or failure, (e) cancer prevention, (f) fetal metabolic programming to prevent the later development of obesity and / or diabetes, (g) maternal and fetal health in gestational diabetes, (h) athletic performance and physical function, (i) obesity, (j) longevity, (k) hepatotoxicity, (l) neurodegenerative disease, (m) prevention of nephropathy, (n) prevention of acetaminophen toxicity. (o) non-alcoholic steatohepatitis (NASH), (p) alcohol hangover, (q) hearing loss, (r) Alzheimer's disease, (s) Parkinson's disease, (t) osteoporosis, (u) high blood pressure, (v) polycystic ovary syndrome (PCOS), (w) atherosclerosis, (x) coronary artery disease, (y) myocardial damage after stress, (z) insufficient immunity after vaccination, (aa) cystic fibrosis, (bb) brain trauma, (cc) concussion, (dd) ototoxicity, (ee) tinnitus, (ff) dizziness, (gg) vertigo, (hh) Meniere's disease, (ii) recovery and survival after trauma, (jj) non-alcoholic fatty liver disease (NAFLD), (kk) neurocognitive function, and (ll) combinations thereof.

[0037] In certain embodiments, glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof are provided to an individual in the same composition or in different compositions. Glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof can be provided to an individual orally.

[0038] In certain embodiments, the glycine derivative is D-allylglycine, N-[bis(methylthio)methylene]glycine methyl ester, Boc-allyl-Gly-OH (dicyclohexylammonium) salt, Boc-D-Chg-OH, Boc-Chg-OH, (R)-N-Boc-(2'-chlorophenyl)glycine, Boc-L-cyclopropylglycine, Boc-L-cyclopropylglycine, (R)-N-Boc-4-fluorophenylglycine, Boc-D-propargylglycine, Boc-(S)-3-thienylglycine, The glycine may be selected from the group consisting of lysine, Boc-(R)-3-thienylglycine, D-α-cyclohexylglycine, L-α-cyclopropylglycine, N-(2-fluorophenyl)-N-(methylsulfonyl)glycine, N-(4-fluorophenyl)-N-(methylsulfonyl)glycine, Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH, N-(2-furoyl)glycine, L-α-neopentylglycine, D-propargylglycine, sarcosine, Z-α-phosphonoglycine trimethyl ester, and mixtures thereof. Glycine and N-acetylcysteine ​​may be included in dipeptides such as, for example, N-acetylcysteinylglycine or cysteinylglycine.

[0039] In one embodiment, there is a method of neutralizing or alleviating drug-induced mitochondrial dysfunction or dysfunction in an individual, comprising providing to the individual an effective amount of a composition comprising glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof. In a particular embodiment, the drug-induced mitochondrial dysfunction or dysfunction is due to an antiviral drug, such as an antiviral drug for HIV or hepatitis. In a particular embodiment, the drug is an anticonvulsant, a psychotropic drug (antidepressant, antipsychotic, barbiturate, anxiolytic), an anticholesterol drug, analgesic / anti-inflammatory drug, antibiotic, antiarrhythmic drug, steroid, antiviral drug, antiretroviral drug, anticancer drug, antidiabetic drug, beta-blocker, or immunization. The drugs include valproate (Depakote), amitriptyline (Elavil), amoxapine, fluoxetine (Prozac), citalopram (Cipramil), chlorpromazine (Thorazine), fluphenazine (Prolixin), haloperidol (Haldol), risperidone (Risperdol), phenobarbital, secobarbital (Seconal), butalbital (Fiornal), amobarbital (Amytal), pentobarbital (Nembutal), alprazolam (Xanax), diazepam (Valiu), The drug may be selected from the group consisting of cis-platinum, diastat), statins, bile acid-cholestyramine, ciprofibrate, ASA (aspirin), acetaminophen (Tylenol), indomethacin (Indocin), naproxen (Aleve), diclofenac, tetracycline, minocycline, chloramphenicol, aminoglycosides, linezolid (Zyvox), amiodarone, interferon, zidovudine, doxorubicin (Adriamycin), cis-platinum, tamoxifen, metformin, or mixtures thereof.

[0040] The foregoing has outlined broadly the features and technical advantages of the present invention in order that the Detailed Description of the Invention may be better understood as set forth below. Additional features and advantages of the present invention which form the subject of the claims of the present invention will be set forth hereinafter. It is to be understood that the concepts and specific embodiments disclosed may be readily utilized as a basis for the designing of modifications or other structures for carrying out the same purposes of the present invention. It is to be recognized that such equivalent constructions do not depart from the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the present invention, both as to its organization and method of operation, together with further objects and advantages thereof, will be better understood from the following description when considered in conjunction with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the scope of the invention.

[0041] For a more complete understanding of the present invention, reference is now made to the following descriptions taken in conjunction with the accompanying drawings, in which: [Brief description of the drawings]

[0042] [Figure 1] FIG. 1 illustrates representative relationships between glutathione deficiency and certain physical conditions. [Diagram 2] FIG. 1 is a graph showing the fractional synthesis rate of GSH in elderly HIV patients compared to controls. [Diagram 3] FIG. 1 is a graph showing GSH concentrations in elderly HIV patients compared to controls. [Figure 4] FIG. 1 is a graphical representation showing fasting oxidation of energy sources in elderly HIV patients compared to controls. [Diagram 5] FIG. 1 is a graph showing C-reactive protein levels in elderly HIV patients before and after oral supplementation with N-acetylcysteine ​​and glycine. [Figure 6] FIG. 1 is a graph showing the lifespan of mice receiving N-acetylcysteine ​​and glycine. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0043] I. Definition

[0048] As used herein, "a" or "an" may mean one or more. As used in the Claims, when used with "comprising," the words "a" or "an" may mean one or more. As used herein, "another" may mean at least a second or more.

[0044]

[0049] As used herein, the term "diabetic complications" in certain embodiments refers to, for example, diabetic nephropathy, neuropathy, retinopathy, diabetic obesity, diabetic dyslipidemia, cardiometabolic syndrome, and combinations thereof.

[0045]

[0050] As used herein, the term "effective amount" refers to the amount of glycine and n-acetylcysteine ​​(or their functional derivatives) required to improve at least one symptom of a medical condition in an individual, in certain embodiments, the medical condition is directly or indirectly caused by an insufficient level of glutathione in the individual. In certain embodiments, the effective amount refers to the amount of glycine and n-acetylcysteine ​​utilized to increase glutathione levels in the individual.

[0046]

[0051] As used herein, the term "elderly" refers to individuals who are at least 60 years of age.

[0047]

[0052] As used herein, the term "oxidative stress" refers to a condition in an individual, or in the cells or tissues of an individual, in which there is an imbalance between the production of reactive oxygen species and the ability to detoxify reactive intermediates or readily repair the resulting damage in a biological system. The natural reducing environment within a cell is maintained by processes that use a constant influx of metabolic energy, and disturbance of this normal redox state can result in toxic effects, e.g., by the production of free radicals and peroxides that damage cellular components such as proteins, lipids, and / or DNA.

[0048] II. General Embodiments

[0053] Embodiments of the present disclosure include methods of increasing blood levels of cysteine ​​and glycine (e.g., cysteinylglycine), increasing intracellular GSH, cysteine, and / or glycine, and / or decreasing CRP levels. In some embodiments, the mechanism of action involves cysteine ​​and / or glycine, but is independent of GSH.

[0049]

[0054] In certain embodiments of the present invention, there are methods and compositions for the treatment of medical conditions caused directly or indirectly by insufficient GSH levels in an individual. The individual may be of any age or health condition, but in certain embodiments, the individual is elderly and susceptible to or has a particular medical or physical condition directly or indirectly associated with insufficient GSH levels. The composition provided to the individual in such cases includes, among other things, at least glycine and n-acetylcysteine ​​as precursor amino acids to promote the elevation of glutathione levels in the individual. Erythrocyte GSH can be measured, or intracellular GSH levels can be measured, for example, by muscle biopsy. Intracellular GSH measurement assays are known in the art (Rahman et al., 2007).

[0050]

[0055] In certain embodiments, one or more medical conditions caused directly or indirectly by reduced levels of cysteine, glycine, and / or GSH are treated or prevented by an effective amount of glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof. In certain embodiments, the medical or physical condition is one or more of the following: (a) muscle weakness, (b) adverse effects of weightlessness, (c) organ damage, (d) cardiac function or failure, (e) cancer prevention, (f) fetal metabolic programming to prevent the later development of obesity and / or diabetes, (g) maternal and fetal health in gestational diabetes, (h) athletic performance and physical function, (i) obesity, (j) longevity, (k) hepatotoxicity, (l) neurodegenerative diseases, (m) prevention of nephropathy, (n) prevention of acetaminophen toxicity, (o) non-alcoholic steatohepatitis, (p) alcohol hangover, (q) hearing loss, (r) Alzheimer's disease, (s ) Parkinson's disease, (t) osteoporosis, (u) hypertension, (v) polycystic ovary syndrome (PCOS), (w) atherosclerosis, (x) coronary artery disease, (y) myocardial damage after stress, (z) insufficient immunity after vaccination, (aa) cystic fibrosis, (bb) brain trauma, (cc) concussion, (dd) ototoxicity, (ee) tinnitus, (ff) dizziness, (gg) vertigo, (hh) Meniere's disease, (ii) recovery and survival after trauma (e.g., after surgery, after sepsis, after blunt or penetrating trauma such as from an accident or physical assault), (jj) non-alcoholic fatty liver disease (NAFLD), and (kk) combinations thereof. An individual may be diagnosed with such condition(s) or may be suspected of having such condition(s) or may be susceptible to such condition(s). The individual may be treated with the methods of the present disclosure as well as with another therapy or therapies.

[0051]

[0056] In certain embodiments, an individual is provided with an effective amount of a composition as described herein for the express purpose of increasing intracellular levels of GSH, cysteine, and / or glycine, and because the individual has been determined to be afflicted with a condition to which such levels are directly or indirectly related. In certain cases, the methods of the present disclosure include diagnosis of such medical condition(s).

[0052] III. Pharmaceutical Compositions

[0057] In certain embodiments, the present invention is directed to a pharmaceutical composition for use in the treatment, prevention, or delay of onset of a medical or physical condition directly or indirectly associated with reduced intracellular GSH levels. In certain embodiments, the composition consists of, consists essentially of, or comprises glycine (or a functional derivative thereof) and N-acetylcysteine ​​(or a functional derivative thereof). A functional derivative of glycine is defined as a glycine derivative that is effective, by itself or together with N-acetylcysteine ​​(or a functional derivative thereof), to increase intracellular GSH levels in an individual. A functional derivative of N-acetylcysteine ​​is defined as an N-acetylcysteine ​​derivative that is effective, by itself or together with glycine (or a functional derivative thereof), to increase intracellular GSH levels in an individual. In certain embodiments, a "cysteine" derivative, i.e., a functional derivative of cysteine ​​that is effective, by itself or together with glycine, in an individual, may be used.

[0053]

[0058] The glycine component and the N-acetylcysteine ​​component can be provided together or separately. In certain embodiments, the composition includes N-acetylcysteinylglycine; cysteinylglycine and all its forms, such as L-cysteinylglycine. Examples of glycine derivatives include at least D-allylglycine, N-[bis(methylthio)methylene]glycine methyl ester, Boc-allyl-Gly-OH (dicyclohexylammonium) salt, Boc-D-Chg-OH, Boc-Chg-OH, (R)-N-Boc-(2'-chlorophenyl)glycine, Boc-L-cyclopropylglycine, Boc-L-cyclopropylglycine, (R)-N-Boc-4-fluorophenylglycine, Boc-D-propargylglycine, Boc-(S)-3-thio ... N-(4-fluorophenyl)-N-(methylsulfonyl)glycine, Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH, N-(2-furoyl)glycine, L-α-neopentylglycine, D-propargylglycine, sarcosine, and Z-α-phosphonoglycine trimethyl ester.

[0054]

[0059] In certain embodiments, the pharmaceutical composition comprises N-acetylcysteine ​​(NAC), L-glycine, L-glycine ethyl ester, and / or di-dipeptide forms, such as cysteinylglycine.

[0055]

[0060] In certain embodiments, glycine is administered at 1.33 mmol / kg / day and NAC is administered at 0.83 mmol / kg / day for a certain period of time. The treatment period may continue for, for example, one or more days, one week, two weeks, three weeks, one month, two months, three months, four months, five months, six months, one year, two years, five years, ten years, fifteen years, twenty years, twenty-five years, thirty years, etc. In some cases, treatment continues for the remainder of the individual's life. In certain embodiments, administration is performed until no detectable symptoms of the medical condition remain. In certain embodiments, administration is performed until a detectable improvement of at least one symptom occurs, and in further cases, until remission continues.

[0056]

[0061] When the present invention is directed to treatment with the compounds of the present invention, the compounds of the present invention can be administered by any of the accepted modes of administration, optionally with suitable pharmaceutical excipients. The compounds can be included in pharma-ceutically acceptable excipients, which can be considered as molecular entities and / or compositions that do not cause adverse, allergic and / or other untoward reactions when administered to an animal, as appropriate. Excipients include any and / or all solvents, dispersion media, coatings, antibacterial and / or antifungal agents, isotonicity agents and / or absorption delaying agents, and the like. The use of such media and / or agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media and / or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.

[0057]

[0062] Thus, administration may be, for example, intravenous, topical, subcutaneous, transdermal, intramuscular, oral, intraarticular, parenteral, peritoneal, intranasal, intravesical, or by inhalation. Suitable sites of administration thus include, but are not limited to, the skin, bronchi, gastrointestinal tract, anus, vagina, eye, bladder, and ear. Formulations may take the form of solids, semi-solids, lyophilized powders, or solutions, such as, for example, tablets, pills, capsules, powders, liquids, suspensions, emulsions, suppositories, retention enemas, creams, ointments, lotions, aerosols, etc., with unit dosage forms suitable for convenient administration of precise dosage amounts being preferred.

[0058]

[0063] The compositions typically include conventional pharmaceutical carriers or excipients, and may further include other medicinal agents, carriers, and adjuvants. Preferably, the compositions are about 5% to 75% by weight of the compound or compounds of the present invention, with the remainder being suitable pharmaceutical excipients. Suitable excipients can be tailored to the particular composition and route of administration by methods well known in the art, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, 18TH ED., Mack Publishing Co., Easton, Pa. (1990).

[0059]

[0064] For oral administration, such excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, dextrose, gelatin, sucrose, magnesium carbonate, etc. The compositions can take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained-release formulations, and the like.

[0060]

[0065] In some embodiments, the pharmaceutical composition takes the form of a pill, tablet or capsule, and thus the composition may contain, in addition to the biologically active compound, any of the following: excipients, such as lactose, sucrose, and dibasic calcium phosphate; disintegrants, such as starch or its derivatives; lubricants, such as magnesium stearate; binders, such as starch, gum arabic, polyvinylpyrrolidone, gelatin, cellulose and its derivatives.

[0061]

[0066] The active compounds of the formulation can be formulated, for example, into suppositories containing about 0.5% to about 50% of the compound of the present invention in a polyethylene glycol (PEG) carrier (e.g., PEG 1000 [96%] and PEG 4000 [4%]).

[0062]

[0067] Liquid compositions can be prepared by dissolving or dispersing the compound (about 0.5% to about 20%), and optionally included pharmaceutical auxiliaries, in a carrier, such as, for example, saline (e.g., 0.9% w / v sodium chloride), aqueous dextrose, glycerol, and ethanol, to form, for example, a solution or suspension for intravenous administration. The active compound can also be formulated into a retention enema.

[0063]

[0068] If desired, the composition to be administered may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, such as sodium acetate, sorbitan monolaurate, or triethanolamine oleate.

[0064]

[0069] For topical administration, the composition is administered in any suitable form, such as a lotion or a transdermal patch, etc. For administration by inhalation, the composition can be administered as a dry powder (e.g., inhalation therapy) or in liquid form by a nebulizer.

[0065]

[0070] Methods for preparing such dosage forms are known or will be apparent to those skilled in the art. See, for example, publications such as Remington's Pharmaceutical Sciences, supra. The composition administered will, in any case, contain an amount of prodrug and / or active compound(s) that is pharma- ceutical effective for the alleviation of the condition being treated when administered in accordance with the teachings of the present invention.

[0066]

[0071] In general, the compounds of the present invention are administered in a therapeutically effective amount, i.e., a dose sufficient to effect treatment, which will vary depending on the individual and condition being treated. Typically, a therapeutically effective daily dose is 0.1-100 mg / kg body weight / day of drug. Most conditions respond to a total dose of about 1 to about 30 mg / kg body weight / day, i.e., about 70 mg to 2100 mg / day for a 70 kg individual.

[0067]

[0072] The stability of the conjugate can be further tuned by chemical modifications such as D-amino acid residues and other peptidomimetic moieties in the polypeptide chain. Furthermore, the stability of the conjugate may also be enhanced by non-natural carbohydrate residues.

[0068]

[0073] The glycine and N-acetylcysteine ​​components may be combined in specific ratios. In certain embodiments, the formulation may include the components in the following representative ratios: for example, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:12, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, 1:85, 1:90, 1:95, 1:100, 1:150, 1:200, 1:300, 1:400, 1:500, 1:600, 1:750, 1:1000, 1:10,000, etc. In certain embodiments, the formulation may include components at the following percentages of the formulation (same or different percentages for each): for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99%.

[0069]

[0074] Glycine (or a functional derivative) and N-acetylcysteine ​​(or a functional derivative) may be administered in the same composition or in different compositions. In embodiments in which glycine (or a functional derivative) and N-acetylcysteine ​​(or a functional derivative) are provided separately, the regimen for these separate administrations may be of any suitable type. In certain embodiments, glycine is provided to an individual before, simultaneously with, or after N-acetylcysteine. The separate administrations may involve the same route of administration but at different times, or may be different routes of administration.

[0070] IV. Combination Therapy

[0075] Alternatively, a treatment of the invention may precede, follow, or both another treatment by a period ranging from minutes to weeks. In embodiments in which the composition(s) of the invention and the other agent are provided separately to an individual, care is taken to generally not allow a significant period of time to pass between each administration, so that the composition of the invention and the other agent can still advantageously exert a combined effect on the cells. In such instances, it is contemplated that both therapies may be administered within about 12 to 24 hours of each other, more preferably within about 6 to 12 hours of each other. However, in some conditions, it may be desirable to extend the treatment period significantly, with days (2, 3, 4, 5, 6, 7 to 8) to weeks elapsing between each administration.

[0071]

[0076] Various combinations can be used, for example, where the treatment of the present invention is "A" and a second therapeutic agent for a medical condition of the present invention, such as a diabetes treatment (by way of example only), is "B": A / B / AB / A / BB / B / AA / A / BA / B / BB / A / AA / B / B / BB / A / B / B B / B / B / AB / B / A / BA / A / B / BA / B / A / BA / B / B / AB / B / A / A B / A / B / AB / A / A / BA / A / A / BB / A / A / AA / B / A / AA / A / B / A

[0072]

[0077] Administration of the inventive composition of the present invention to patients will follow standard procedures for administration of drugs, taking into account the toxicity of the molecule, if applicable. It is expected that treatment cycles will be repeated as necessary. It is also contemplated that various standard therapies and surgical interventions may be applied in combination with the described therapies.

[0073] V.Kit

[0078] Therapeutic kits relating to the compositions of the present invention comprise another aspect of the present invention. Such kits will generally contain, in suitable container means, the inventive composition of the present invention. The kits may have a single container means which contains the composition of the present invention or the kits may have separate container means for the composition of the present invention and for other reagents that may be included within such kits.

[0074]

[0079] The components of the kit may be provided as liquid solution(s) or as dry powder(s). When the components are provided in a liquid solution, the liquid solution may be an aqueous or non-aqueous solution, with a sterile aqueous or non-aqueous solution being particularly preferred. When the reagents or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.

[0075]

[0080] The container means generally includes at least one vial, test tube, flask, bottle, syringe, and other container means into which the composition can be placed, and preferably appropriately divided. If a second agent is provided, the kit also generally includes a second vial or other container into which the agent can be placed. The kit of the present invention also typically includes a means for containing the agent container in a tightly confined manner for commercial sale. Such containers can include, for example, injection-molded or blow-molded plastic containers into which the desired vials are held.

[0076]

[0081] In the kits of the invention, glycine (or a functional derivative thereof) and N-acetylcysteine ​​(or a functional derivative thereof) may be provided separately or together in a mixture. VI. Working Examples

[0082] The following examples are provided to demonstrate preferred embodiments of the present invention. Those skilled in the art should understand that the techniques disclosed in the examples are in accordance with the methods of the present invention that the inventors have found to work well in implementing the present invention, and therefore can be considered to constitute the preferred modes for its implementation. However, those skilled in the art should understand that, upon consideration of this disclosure, many changes can be made in the specific embodiments disclosed, and still obtain the same or similar results, without departing from the spirit and scope of the present invention. EXAMPLES

[0077] Example 1 Metabolic basis of sarcopenic obesity in aging: role of glutathione

[0083] Elderly people are at the highest risk of becoming overweight or developing obesity. Along with the prevalence of muscle mass loss in this population, elderly people develop a phenotype of "sarcopenic obesity" with reduced muscle strength and reduced quality of life, but the pathogenesis is poorly understood and there is no effective therapy. Translational studies in humans and rodents have found that the deficiency of glutathione (GSH), the most abundant endogenous antioxidant, in aging is associated with mitochondrial dysfunction, which in some embodiments provides a mechanistic explanation for the development of sarcopenic obesity in elderly people. GSH deficiency in elderly people is caused by reduced synthesis due to the limited availability of its precursor amino acids cysteine ​​and glycine. Short-term supplementation of these amino acids is sufficient to correct the deficiency itself and restore the intracellular synthesis and concentration of GSH. Compared to fasted healthy young human controls, fasted GSH-deficient elderly subjects had severe impairment of mitochondrial fatty acid oxidation (which may promote fat storage) along with increased carbohydrate oxidation (which may contribute to muscle decline). Since the preferred mitochondrial energy source in the fasted state is fatty acids, not glucose, this unusual reversal in energy source preference during fasting suggests impaired mitochondrial energy usage. Interestingly, restoration of GSH synthesis in these elderly subjects by supplementation with the precursors cysteine ​​and glycine for 2 weeks resulted in a complete restoration of fasted mitochondrial fatty acid and carbohydrate oxidation to the levels seen in young controls. Based on these data, it is believed that impaired mitochondrial fatty acid oxidation shifts the oxidation of energy sources to glucose to meet energy demands. In the fasted state, glucose is provided by gluconeogenesis, with a large contribution from muscle protein, which results in reduced muscle protein (and therefore muscle mass) as well as deficiencies in cysteine ​​and glycine (known gluconeogenic amino acids), further amplifying the GSH deficiency. Loss of muscle mass can in turn lead to loss of muscle strength.Supplementation with cysteine ​​and glycine may correct GSH deficiency, break this vicious cycle, correct mitochondrial fatty acid oxidation (thus lowering total body fat), reduce carbohydrate oxidation (thus avoiding muscle protein loss and increasing lean mass), and increase muscle strength. This observation is supported by a study in HIV patients with biological aging, in which correction of GSH deficiency by cysteine ​​and glycine supplementation (using the same doses and duration as in the elderly study) was accompanied by restoration of fasting mitochondrial oxidation of energy sources, a 3.5 pound loss in total body fat, a 1.9 pound increase in lean mass, and a significant increase in muscle strength in the dominant and non-dominant arms within a two-week period.

[0078] Example 2 Prevention and treatment of sarcopenia, sarcopenic obesity, cachexia and muscle wasting

[0084] Sarcopenia is the degenerative loss of skeletal muscle mass, quality, and strength associated with aging. Sarcopenia may also be associated with disuse and weightlessness or weightlessness. Cachexia is a complex metabolic wasting syndrome characterized by weight loss, muscle atrophy, weakness, and fatigue associated with various chronic diseases, such as cancer, HIVAIDS, COPD, neurodegenerative diseases (such as multiple sclerosis), congestive heart disease, tuberculosis, and kidney disease. Sarcopenia may be associated with an increase in body fat mass, i.e., sarcopenic obesity, and cachexia may or may not be associated with a decrease in body fat mass.

[0079]

[0085] These conditions represent a prime target for prevention and treatment to elevate intracellular GSH and improve muscle health in mammals by providing cysteine ​​and glycine. Improvement of GSH by administering its precursors, cysteine ​​and glycine, was associated with improved physiological patterns of mitochondrial energy source oxidation, reduced total body fat, waist circumference and insulin resistance, and increased lean body mass and muscle strength in elderly HIV-infected patients, suggesting that this method may prevent and reverse sarcopenia, sarcopenic obesity, and cachexia.

[0080] Example 3 Prevention and Treatment of Drug and Other Toxicity

[0086] A variety of drugs, such as acetaminophen and antiretroviral drugs, cause mitochondrial toxicity and / or hepatotoxicity. Specific drugs that cause mitochondrial toxicity include at least anticonvulsants, psychotropic drugs (antidepressants, antipsychotics, barbiturates, and anxiolytics), anticholesterol drugs, analgesics / anti-inflammatory drugs, antibiotics, antiarrhythmic drugs, steroids, antivirals, antiretrovirals, anticancer drugs, antidiabetics, beta-blockers, and immunizations. Specific drugs include valproate, amitriptyline, amoxapine, fluoxetine, citalopram, chlorpromazine, fluphenazine, haloperidol, risperidone, phenobarbital, secobarbital, butalbital, amobarbital, pentobarbital, alprazolam, diazepam, statins, bile acid-cholestyramine, ciprofibrate, fenofibrate, aspirin, acetaminophen, indomethacin, naproxen, diclofenac, tetracycline, minocycline, chloramphenicol, tenofovir, darunavir, ribavirin, telaprevir, aminoglycosides, linezolid, amiodarone, interferon, zidovudine, doxorubicin, cis-platinum, tamoxifen, and metformin.

[0081]

[0087] In certain embodiments, NAC and / or glycine are administered to an individual to prevent, treat, or reduce the adverse effects of mitochondrial and / or hepatotoxicity, hi certain embodiments, oxidative stress and / or other toxicities associated with GSH deficiency are treated by the methods of the present disclosure.

[0082]

[0088] In certain embodiments, there are methods for preventing and treating acetaminophen toxicity associated with hepatotoxicity. Hepatotoxicity is a significant problem during drug development and for the use of many established drugs. For example, acetaminophen overdose is currently the most common cause of acute liver failure in the United States. Hepatic mitochondria are a significant target of drug toxicity, which is directly or indirectly related to the formation of reactive metabolites. Acetaminophen (Tylenol®, paracetamol, N-acetyl-p-aminophenol; APAP) is an over-the-counter analgesic and antipyretic drug. Acetaminophen is also often used in combination with hydrocodone, propoxyphene, codeine, and oxycodone, as well as many prescription narcotics. At therapeutic doses, acetaminophen has analgesic and antipyretic effects similar to aspirin and ibuprofen, but the therapeutic window is very narrow. Acetaminophen, even at doses within the recommended range, is the leading cause of acute liver failure, and is responsible for tens of thousands of calls and hospitalizations to poison control centers and hundreds of deaths each year. Both alcohol intake and fasting (due to illness, anorexia, or nutritional disorders) greatly increase the risk of liver damage from acetaminophen.

[0083]

[0089] Older age, alcohol use, and fasting (e.g., due to disease, anorexia, or malnutrition), as well as even the metabolic products of acetaminophen itself, greatly increase the risk of liver damage by decreasing levels of glutathione, an antioxidant that helps the liver detoxify acetaminophen. Even at standard doses, metabolism of acetaminophen in humans releases small amounts of a toxic substance, N-acetyl-benzoquinoneimine (or NAPQI). Overdoses produce even larger amounts of this toxin. There is a fine line between safe and dangerous doses of acetaminophen; even doses slightly above the maximum recommended dose of 4 g / day can cause liver damage.

[0084]

[0090] Utilizing optimal intracellular glutathione concentration in the liver is a natural prevention and treatment for acetaminophen toxicity. Administration of N-acetylcysteine ​​is the primary treatment for acetaminophen overdose-induced hepatotoxicity due to its ability to maintain hepatic glutathione reserves. In certain embodiments, increasing hepatic GSH levels with NAC / glycine before, with, and / or after acetaminophen alleviates the toxic effects of acetaminophen to normal levels.

[0085] Example 4 Improved physical performance

[0091] The disclosed methods and / or compositions may be provided to individuals to improve physical performance, to prevent muscle loss by enhancing the effectiveness of exercise, to recover from intense exercise, or to reverse the loss of lean muscle mass caused by non-disease conditions that accelerate aging and muscle loss in otherwise physically healthy young individuals (astronauts (weightlessness), marathon runners, firefighters, elite athletes, etc.). Furthermore, endurance activity specifically increases oxidative stress, which may be of particular concern in older athletes who may already have a deficiency of intracellular GSH. Thus, in certain embodiments, the disclosed methods prevent and / or treat exercise oxidative stress.

[0086] Example 5 lifespan

[0092] Supplemental feeding of aged mice with cysteine ​​(as n-acetylcysteine) and glycine is sufficient to increase the antioxidant glutathione levels. Restoration of glutathione in these aged mice resulted in a significant restoration of oxidation of mitochondrial energy sources. Since these beneficial changes are useful in influencing lifespan, it was tested whether supplementation of mice with cysteine ​​(as n-acetylcysteine) and glycine in their diet would extend their lifespan. The study was carried out as follows: 60-week-old mice were tested in two groups (7 mice (2 females and 5 males) in each group), both groups matched for sex, age and weight. One group had free access to normal chow, while the second group was fed a chow that additionally contained cysteine ​​(as n-acetylcysteine) and glycine. However, the content of both chows was identical in terms of calories and protein-nitrogen per gram of chow. That is, both chows were isocaloric and isonitrogenous. Food weight was monitored and food intake was similar in both groups. Animals had free access to their respective food and water, and lifespan was recorded as the primary endpoint. Results showed that mice receiving the cysteine ​​and glycine supplemented food lived an average of 34 weeks longer, corresponding to a 35% increase in lifespan (Figure 6).

[0087] Example 6 HIV in older adults

[0093] HIV-infected patients over the age of 50 have been reported to have accelerated functional decline with loss of muscle mass, muscle strength, and functional limitations comparable to geriatric non-HIV patients, but the pathogenesis of these deficiencies is not fully understood and there are no effective therapies. Recognizing this, the Centers for Disease Control has suggested that the cutoff for "older age" in HIV patients begins at age 50.

[0088]

[0094] In certain embodiments of the present disclosure, the decline in function in elderly HIV-infected patients is associated with mitochondrial dysfunction. Mitochondria rely on antioxidants to defend against harmful reactive oxygen species and oxidative stress. Glutathione (GSH), the most abundant endogenous intracellular antioxidant and a key component of mitochondrial antioxidant defense, is known to be deficient in HIV patients. With regard to the mechanisms contributing to GSH deficiency in elderly HIV patients, this GSH deficiency occurs due to a severe decline in GSH synthesis caused by a deficiency of its two precursor amino acids, cysteine ​​and glycine. Oral nutritional supplementation with cysteine ​​and glycine for two weeks corrected the deficiency of these amino acids, increased GSH synthesis, improved intracellular GSH concentration, and reduced ROS levels and oxidative damage. Under physiological conditions, fatty acids (FAs) are the energy source of choice in the fasting state, not glucose. Elderly HIV patients with GSH deficiency had significantly impaired fasting FA oxidation and enhanced fasting glucose oxidation, suggesting mitochondrial dysfunction. Improvement of GSH concentrations resulted in significantly increased fasting mitochondrial FA oxidation and decreased glucose oxidation. These changes were accompanied by significant increases in lean body mass and muscle strength. Interestingly, the muscle strength of these patients increased significantly when GSH levels were elevated. That is, whereas in the GSH-deficient state, the muscle strength of the patients was comparable to that of an 80-year-old non-HIV person, with the increase in GSH, the muscle strength of the patients increased to that of a 70-year-old person. In effect, these elderly HIV patients became 10 years "younger" within a 2-week period with the improvement in GSH.

[0089]

[0095] We can investigate whether GSH deficiency contributes to the loss of muscle mass, muscle strength, functional limitations, and quality of life in older HIV patients, and test whether supplementation with cysteine ​​and glycine to correct GSH deficiency reverses these deficiencies. For example, an open-label study can be conducted in 10 older HIV patients aged 50-60 years and 10 non-HIV controls (matched for age, sex, and BMI). Based on published data, 8 subjects are needed as a case size, and 10 subjects can be tested, allowing for 20% attrition. All subjects may be tested at baseline, and only HIV subjects may be tested again after 12 weeks of cysteine ​​and glycine supplementation. We can test whether GSH deficiency in older HIV patients correlates with impaired fasting mitochondrial oxidation of energy sources and reduced muscle protein compared to non-HIV controls, and whether these defects can be reversed by supplementation with cysteine ​​and glycine.

[0090]

[0096] In certain embodiments for elderly HIV patients, GSH deficiency leads to incomplete oxidation of mitochondrial energy sources during fasting, elevated glucose oxidation, and reduced muscle protein, and restoration of GSH can reverse these defects. Without being bound by theory, GSH deficiency impairs mitochondrial NEFA oxidation during fasting, forcing a shift to glucose oxidation to meet energy demands. Glucose in the fasting state is primarily sourced from muscle protein through gluconeogenesis, which leads to muscle loss and cysteine ​​and glycine deficiency (Figure 1). Correcting GSH deficiency by supplementing with cysteine ​​and glycine restores mitochondrial FA oxidation during fasting and reduces glucose oxidation, thereby increasing muscle mass by reducing the loss of muscle protein toward gluconeogenesis. With regard to such considerations, measurements of muscle GSH, cysteine ​​and glycine levels (HPLC), fasting NEFA and glucose oxidation (calorimetry), muscle protein loss (stable isotope measurements), and muscle mass measurements (DEXA, total body potassium and nitrogen scans) can be performed.

[0091]

[0097] It can be tested whether GSH deficiency in elderly HIV patients correlates with reduced muscle mass, strength and function compared to non-HIV controls, and whether restoration of GSH restores muscle strength and function to the same level as matched non-HIV controls. In certain embodiments, GSH deficiency in elderly HIV patients is the root cause of the reduced muscle strength and function, and restoration of GSH can improve muscle strength and function to the level of matched non-HIV groups. In such studies, measurements of muscle strength (e.g., by forearm grip strength via dynamometry) and muscle function (e.g., by 6-minute walk) can be performed.

[0092]

[0098] Elderly HIV patients have poor mitochondrial oxidation and reduced muscle protein, with unknown pathogenesis. By 2015, over 50% of HIV patients are expected to be elderly (over 50 years old), resulting in increased human burden and medical costs due to these deficiencies. The present disclosure provides prevention and reversal of muscle loss, increased muscle strength, improved muscle function and quality of life in elderly HIV patients, reducing medical costs in the growing elderly HIV patient population. In certain embodiments, GSH deficiency is a novel and highly significant risk factor for muscle loss in elderly HIV patients, and providing a therapy based on cysteine ​​and glycine supplementation can correct GSH deficiency and reverse muscle loss. In certain embodiments, muscle mass and strength, exercise capacity can be increased, and quality of life can be improved. Embodiments of the present disclosure provide a novel, simple, safe, effective, and inexpensive nutritional plan for correcting GSH deficiency in elderly HIV patients with cysteine ​​and glycine.

[0093]

[0099] In certain embodiments, GSH deficiency is the root cause of impaired mitochondrial oxidation of energy sources during fasting, and the decline in muscle mass, strength, and function in elderly HIV patients, contributing to accelerated functional decline. Using innovative stable isotope tracer-based procedures, calorimetry, DXA, total body potassium and nitrogen scans, strength measurements, and functional tests, outcome measurements can be performed at the whole body level (NEFA and glucose oxidation, and muscle decline) and tissue level (loss of muscle GSH and muscle protein), and cysteine ​​and glycine supplementation is shown to produce benefits. The embodiments of the present disclosure provide a novel, simple, safe, effective, and inexpensive nutritional plan using cysteine ​​and glycine to correct the defects in mitochondrial oxidation of energy sources, the decline in muscle protein, muscle mass, and strength, and quality of life in elderly HIV patients.

[0094]

[0100] HIV and GSH deficiency: RBC-GSH levels were measured in young (age 30-40 years, n=10) and older (age 50-60 years, n=20) HIV patients, low GSH was found in all patients, but age was significantly associated with lower GSH concentrations (P<0.0001). Further analysis showed that 55-year-old HIV patients had GSH levels similar to 70-year-old non-HIV individuals.

[0095]

[0101] GSH kinetics in elderly HIV patients (Fig. 2, Fig. 3): GSH kinetics was examined in eight elderly GSH-deficient HIV patients (approximately 55 years old) before and after supplementation with cysteine ​​and glycine as GSH precursors. Results compared with histories of GSH-replete non-HIV controls (n=8) showed severe intracellular deficiencies of cysteine ​​and glycine in elderly HIV patients, which improved with supplementation. As shown, before supplementation, GSH-FSR levels were 58% lower and GSH levels were 57% lower in HIV subjects (compared to controls). After supplementation, GSH-FSR (FSR is the fractional synthetic rate) and GSH levels increased by 120% and 53%, respectively.

[0096]

[0102] Energy oxidation during fasting in elderly HIV subjects (Figure 4): After a 16-h fast, GSH-deficient elderly HIV subjects had significantly lower NEFA oxidation and significantly higher carbohydrate (CARB) oxidation compared to non-HIV controls. Restoration of GSH synthesis increased NEFA oxidation by 46% and decreased carbohydrate oxidation by 49%. (*=p<0.05, Φ=p<0.01).

[0097]

[0103] Improvement in GSH increased lean body mass and muscle strength: Improvement in GSH led to a significant increase in lean body mass of 0.9 kg (p=0.003) and increased muscle strength in both forearms (p<0.01).

[0098]

[0104] Thus, elderly HIV patients have GSH deficiency due to reduced synthesis (caused by reduced availability of the GSH precursors cysteine ​​and glycine), which is associated with impaired mitochondrial oxidation of energy sources and reduced muscle mass and strength. Supplementation with cysteine ​​and glycine for two weeks increases GSH levels. In certain embodiments, supplementation for a longer period of 12 weeks fully restores GSH concentrations and reverses muscle and functional decline in elderly HIV patients.

[0099] Example 7 C-reactive protein

[0105] C-reactive protein (CRP) is an acute phase protein found in plasma and synthesized by the liver. CRP levels are elevated in response to inflammation and are therefore considered a biomarker for conditions associated with increased inflammation. CRP has also been identified as a biomarker for cardiovascular disease, with levels above 3 μg / mL considered undesirable and levels below 1 μg / mL considered optimal. Elevated CRP has also been associated with diabetes, HIV and aging. Treatments to lower CRP levels are limited. Potent cholesterol-lowering drugs in the class of drugs known as statins can lower CRP levels.

[0100]

[0106] Elderly HIV patients with glutathione deficiency had high levels of CRP, and when glutathione levels were increased using oral nutritional supplementation with cysteine ​​(as n-acetylcysteine) and glycine, CRP was significantly reduced (p<0.05) (Figure 5).

[0101] Example 8 Improves mitochondrial dysfunction after drug intake

[0107] Certain drugs cause toxicity because their mechanism of action results in mitochondrial dysfunction or dysfunction. In certain embodiments, a method is provided to an individual with an effective amount of a composition comprising glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof to neutralize or alleviate drug-induced mitochondrial dysfunction or dysfunction. The toxicity caused by a drug can be a variety of things that cause mitochondrial dysfunction or dysfunction, but in certain embodiments, the drug is an antiviral drug, such as an HIV drug and a hepatitis drug. In certain embodiments, drug toxicity can also be caused or exacerbated by depletion of GSH, either before or after treatment.

[0102]

[0108] Drugs that cause mitochondrial toxicity include at least anticonvulsants, psychotropic drugs (antidepressants, antipsychotics, barbiturates, anxiolytics), anticholesterol drugs, analgesics / anti-inflammatory drugs, antibiotics, antiarrhythmic drugs, steroids, antivirals, antiretrovirals, anticancer drugs, antidiabetics, beta-blockers, and immunizations.

[0103]

[0109] In certain cases, the medications may be valproate (Depakote), amitriptyline (Elavil), amoxapine, fluoxetine (Prozac), citalopram (Cipramil), chlorpromazine (Thorazine), fluphenazine (Prolixin), haloperidol (Haldol), risperidone (Risperdol), phenobarbital, secobarbital (Seconal), butalbital (Fiornal), amobarbital (Amytal), pentobarbital (Nembutal), alprazolam (Xanax), diazepam (Valium, Dale). Iastat), statins, bile acid-cholestyramine, ciprofibrate, ASA (aspirin), acetaminophen (Tylenol), indomethacin (Indocin), naproxen (Aleve), diclofenac, tetracycline, minocycline, chloramphenicol, aminoglycosides, linezolid (Zyvox), amiodarone, interferon, zidovudine, doxorubicin (Adriamycin), cis-platinum, tamoxifen, metformin, cystuc, or mixtures thereof.

[0104]

[0110] In situations such as in an individual requiring administration of a drug known or suspected to have drug toxicity due to mitochondrial dysfunction or depletion of GSH, the individual may also be provided with a composition comprising glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof. In certain cases, the drug having mitochondrial toxicity is administered to the individual at the same time and / or before and / or after glycine or a functional derivative thereof and N-acetylcysteine ​​or a functional derivative thereof are administered to the individual.

[0105] Example 9 Physiological Effects of Increasing GSH Concentrations

[0111] 1. HIV and TNF-α: Eight HIV patients had plasma TNF-α levels measured before and after 2 weeks of supplementation with cysteine ​​and glycine to increase GSH levels. Data showed that TNF-α decreased from 34.6±7.5 to 27.8±4.7 (p=0.00049).

[0106]

[0112] 2. Neurocognitive Data: Neurocognitive assessments were performed on three HIV patients before and after 12 weeks of supplementation with cysteine ​​and glycine to increase GSH levels. The data showed improvement in neurocognitive function, as shown below.

[0113] Trail Making Test (Overall Index) 38±3 to 45±5

[0114] MAE III 30±5 to 45±4

[0115] MOCA (Montreal Cognitive Assessment) 76±8 to 86±6

[0107]

[0116] 3. Improvement of diastolic dysfunction:

[0117] Two groups of male mice (age 30-35 months) were studied. One group was fed a chow diet (control - CON) and the other group's diet was supplemented with cysteine ​​and glycine (NacGly). Non-invasive measurements of aortic outflow, transmitral flow, aortic stiffness, and echocardiographic measurements of the left ventricle, as well as atrial anatomy and function, were compared before and after 7 weeks of feeding (n=4 per group). NacGly mice showed significant improvements in transmitral flow parameters compared to unchanged controls. NacGly mice also had significantly improved isovolumic relaxation time (Con 23.1+2.5 vs. NacGly 19.2+0.7 msec, p<0.05), isovolumic contraction time (Con 26.3+4.6 vs. NacGly 13.9+0.3 msec, p<0.05), and peak early filling velocity (Con 67+4 vs. NacGly 78+5 cm / sec, p<0.05). The conclusion of this study is that nutritional supplementation with cysteine ​​(as n-acetylcysteine) and glycine improves diastolic function in aged mice.

[0108]

[0118] 4. Liver fat in HIV patients: Liver fat content was examined by MRI in one subject before and after 12 weeks of supplementation with cysteine ​​and glycine. The results were as follows:

[0119] Liver fat by MRI

[0120] Right anterior lobe (%)

[0121] Right posterior lobe (%)

[0122] Baseline (before supplementation)

[0123] 7.0+ / -0.9%

[0124] 8.5+ / -1.2%

[0125] Follow-up (after resupply)

[0126] 5.0+ / -1.1%

[0127] 6.0+ / -1.2%

[0109]

[0128] 5. Liver Fat in Diabetic Mice: Two groups of mice were studied after one year of exposure to severe, uncontrolled diabetes. From the time of induction of diabetes, one group (treatment) received a supplement of cysteine ​​(as n-acetylcysteine) and glycine, while the other (control) group received a control diet that was isonitrogenous and isocaloric to the first group. Histological evaluation showed that the incidence of fatty liver was 95-100% in the control group receiving the isonitrogenous / isocaloric diet, whereas the incidence of fatty liver was only 2-5% in the treatment group receiving the cysteine / glycine diet. Liver fat was quantified and was significantly lower in the treatment mice.

[0110]

[0129] 5. Muscle protein breakdown: Muscle protein breakdown was examined in three elderly HIV patients before and after 12 weeks of supplementation with cysteine ​​(as n-acetylcysteine) and glycine using the tracer 3-methylhistidine. Results showed a significant reduction in myofibrillar protein breakdown. These data suggest that improving glutathione with cysteine ​​and glycine in aging may reduce muscle breakdown and be effective in treating sarcopenia.

[0111]

[0130] Breakdown rate of muscle proteins in myofibrils:

[0131] Before supplementation: 203±59mg / kgLBM / hour

[0132] After supplementation: 137±15mg / kgLBM / hour

[0112] Example 10 Example of n-acetylcysteine ​​and glycine supplementation

[0133] In mouse studies, the effects of n-acetylcysteine ​​and glycine improve mitochondrial function and muscle strength in aged mice, in certain embodiments, this occurs via glutathione. In some embodiments, n-acetylcysteine ​​and glycine supplementation reduces liver fat in mice.

[0113]

[0134] In certain embodiments, n-acetylcysteine ​​and glycine supplementation in HIV patients improves mild neurocognitive impairment in HIV-infected patients, improves muscle strength and exercise capacity, and / or restores glutathione to parity with age-matched controls.

[0114]

[0135] In certain embodiments, n-acetylcysteine ​​and glycine supplementation improves cognitive impairment within at least four weeks in ongoing studies in geriatric humans.

[0115] Example 11 HIV physical and neurocognitive data

[0136] HIV-infected patients have been reported to have accelerated aging with a decline in physical function. HIV patients have also been reported to have significant impairments in cognitive function. To evaluate the effects of cysteine ​​and glycine supplementation, we tested eight HIV patients before and after 12 weeks of cysteine ​​(as n-acetylcysteine) and glycine supplementation. The control group was also eight HIV-negative individuals matched for age, sex, and BMI. Outcome measurements included physical function (walking speed) and neurocognitive function (trail making test and MAE III).

[0116]

[0137] Results showed that compared with non-HIV controls, HIV-infected patients had significantly slower walking speed (1.3±0.1 vs. 1.06±0.04 m / s, p<0.001) and showed more significant cognitive impairment as measured by the Trail Making Test A (34.6±3.6 vs. 62.6±6.1 s, p<0.01) and Trail Making Test B (53.8±7.2 vs. 117.5±5.0 s, p<0.01) and the Multilingual Aphasic Examination III (41.0±3.5 vs. 28.9±3.2 words, p<0.01). After 12 weeks of supplementation, compared to pre-supplementation levels, the walking speed of HIV patients was restored to a similar and comparable level to HIV-negative controls (1.06±0.04 vs. 1.30±0.04 m / s, p<0.01), suggesting that cysteine ​​and glycine supplementation may reverse accelerated aging in HIV patients. This is indicated by a significant increase in cognitive function (pre-supplementation vs. post-supplementation levels) as seen in improved scores on Trail Making Test A (62.6±6.1 vs. 46.4±4.4 s, p<0.01) and B (117.5±5.0 vs. 69.8±5.4 s, p<0.01) and MAE III (28.9±3.2 vs. 34.6±2.0 words, p<0.01).

[0117]

[0138] Conclusion: Cysteine ​​and glycine supplementation reverses glutathione deficiency and reverses functional decline and cognitive function in HIV-infected patients. Collectively, these data support the efficacy of cysteine ​​and glycine supplementation in reversing accelerated aging in HIV-infected patients.

[0118] References

[0139] All patents and publications mentioned in this specification are indicative of the level of those skilled in the art to which this invention pertains. All patents and publications in this specification are incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference in its entirety. [Non-patent literature]

[0140] Al-Turk WA,Stohs SJ,el-RashidyFH,Othman S. Changes inglutathione and its metabolizing enzymes in humanerythrocytes and lymphocyteswith age. J Pharm Pharmacol 1987;39:13-6.

[0141] Bella DL,Hahn C,Stipanuk MH. Effectsof nonsulfur and sulfuramino acids on the regulation of hepatic enzymes ofcysteine metabolism. Am JPhysiol 1999;277:E144-53.

[0142] Boirie Y,Gachon P,Beaufrere B. Splanchnicand whole-bodyleucine kinetics in young and elderly men. Am J Clin Nutr1997;65:489-95.

[0143] Campisi A,Di Giacomo C,Russo A,et al.Antioxidant systems inrat lens as a function of age:effect of chronicadministration of vitamin E andascorbate. Aging(Milano)1999;11:39-43.

[0144] Campbell WW,Crim MC,Dallal GE,YoungVR,Evans WJ. Increasedprotein requirements in elderly people:new data andretrospective reassessments.Am J Clin Nutr 1994;60:501-9.

[0145] Castorina C,Campisi A,Di GiacomoC,Sorrenti V,Russo A,VanellaA. Lipid peroxidation and antioxidant enzymaticsystems in rat retina as afunction of age. Neurochem Res 1992;17:599-604.

[0146] Cresenzi CL,Lee JI,Stipanuk MH. Cysteineis the metabolicsignal responsible for dietary regulation of hepatic cysteinedioxygenase andglutamate cysteine ligase in intact rats. J Nutr2003;133:2697-702.

[0147] Erden-Inal M,Sunal E,Kanbak G. Age-relatedchanges in theglutathione redox system. Cell Biochem Funct 2002;20:61-6.

[0148] Farooqui MY,Day WW,Zamorano DM. Glutathioneand lipidperoxidation in the aging rat. Comp Biochem Physiol B 1987;88:177-80.

[0149] Fereday A,Gibson NR,Cox M,PacyPJ,Millward DJ. Proteinrequirements and ageing:metabolic demand and efficiencyof utilization. Br JNutr 1997;77:685-702.

[0150] Fidelus RK,Tsan MF. Glutathione andlymphocyte activation:afunction of ageing and auto-immune disease. Immunology1987;61:503-8.

[0151] Furukawa T,Meydani SN,Blumberg JB. Reversalof age-associateddecline in immune responsiveness by dietary glutathionesupplementation in mice.Mech Ageing Dev 1987;38:107-17.

[0152] Grimble RF,Jackson AA,Persaud C,WrideMJ,Delers F,Engler R.Cysteine and glycine supplementation modulate themetabolic response to tumornecrosis factor alpha in rats fed a low proteindiet. J Nutr 1992;122:2066-73.

[0153] Hashimoto K,Takasaki W,YamotoT,Manabe S,Sato I,Tsuda S. Effectof glutathione(GSH)depletion on DNA damageand blood chemistry in aged and youngrats. J Toxicol Sci 2008;33:421-9.

[0154] Jackson AA,Gibson NR,Lu Y,Jahoor F. Synthesisof erythrocyteglutathione in healthy adults consuming the safe amount ofdietary protein. Am JClin Nutr 2004;80:101-7.

[0155] Jahoor F,Wykes LJ,Reeds PJ,HenryJF,del Rosario MP,Frazer ME.Protein-deficient pigs cannot maintain reducedglutathione homeostasis whensubjected to the stress of inflammation. J Nutr1995;125:1462-72.

[0156] Lang CA,Naryshkin S,SchneiderDL,Mills BJ,Lindeman RD. Lowblood glutathione levels in healthy aging adults. JLab Clin Med 1992;120:720-5.

[0157] Liu R,Choi J. Age-associated declinein gamma-glutamylcysteinesynthetase gene expression in rats. Free Radic BiolMed 2000;28:566-74.

[0158] Liu H,Wang H,Shenvi S,Hagen TM,LiuRM. Glutathione metabolismduring aging and in Alzheimer disease. Ann N Y AcadSci 2004;1019:346-9.

[0159] Loguercio C,Taranto D,VitaleLM,Beneduce F,Del Vecchio BlancoC. Effect of liver cirrhosis and age on theglutathione concentration in theplasma,erythrocytes,and gastric mucosa of man.Free Radic Biol Med1996;20:483-8.

[0160] Lyons J,Rauh-Pfeiffer A,Yu YM,et al. Bloodglutathionesynthesis rates in healthy adults receiving a sulfur aminoacid-free diet. ProcNatl Acad Sci U S A 2000;97:5071-6.

[0161] Matsubara LS,Machado PE. Age-relatedchanges of glutathionecontent,glutathione reductase and glutathione peroxidaseactivity of humanerythrocytes. Braz J Med Biol Res 1991;24:449-54.

[0162] Morais JA,Gougeon R,Pencharz PB,JonesPJ,Ross R,Marliss EB.Whole-body protein turnover in the healthy elderly. Am JClin Nutr1997;66:880-9.

[0163] Rahman,I.,Aruna Kode1,Saibal KBiswas. Assay for quantitativedetermination of glutathione and glutathionedisulfide levels using enzymaticrecycling method. Nature Protocols2006;1(6):3159-3165.

[0164] Rebrin I,Sohal RS. Pro-oxidant shiftin glutathione redox stateduring aging. Adv Drug Deliv Rv 2008;60:1545-52.

[0165] Reid M,Jahoor F. Methods formeasuring glutathioneconcentration and rate of synthesis. Curr Opin Clin NutrMetab Care2000;3:385-90.

[0166] Rikans LE,Hornbrook KR. Lipidperoxidation,antioxidantprotection and aging. Biochim Biophys Acta1997;1362:116-27.

[0167] Rizvi SI,Maurya PK. Markers ofoxidative stress in erythrocytesduring aging in humans. Ann N Y Acad Sci2007;1100:373-82.

[0168] Samiec PS,Drews-Botsch C,Flagg EW,etal. Glutathione in humanplasma:decline in association with aging,age-relatedmacular degeneration,anddiabetes. Free Radic Biol Med 1998;24:699-704.

[0169] Stohs SJ,Lawson T,Al-Turk WA. Changesin glutathione andglutathione metabolizing enzymes in erythrocytes andlymphocytes of mice as afunction of age. Gen Pharmacol 1984;15:267-70.

[0170] Sweeney MH,Truscott RJ. An impedimentto glutathione diffusionin older normal human lenses:a possible preconditionfor nuclear cataract. ExpEye Res 1998;67:587-95.

[0171] Toroser D, Sohal RS. Age-associated perturbations in glutathionesynthesis in mouse liver. Biochem J2007;405:583-9.

[0172] Young VR. Amino acids and proteins inrelation to the nutrition of elderly people. Age Aging 1990;19:S10-24.

[0119]

[0173] Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made therein without departing from the present invention as defined by the claims. Moreover, the scope of the present specification is not intended to be limited to the particular embodiments of the processes, apparatus, manufacture, compositions of matter, means, methods and steps described herein. As can be readily understood from the present disclosure, it is possible to utilize existing or later developed processes, apparatus, manufacture, compositions of matter, means, methods or steps that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein. Accordingly, the claims are intended to include within their scope such processes, apparatus, manufacture, compositions of matter, means, methods or steps.

Claims

1. A composition for treating cardiac diastolic dysfunction in an individual with glutathione deficiency, comprising glycine or a functional derivative thereof and N-acetylcysteine, or comprising a dipeptide of glycine and N-acetylcysteine, said glycine functional derivative being selected from the group consisting of D-allylglycine, N-[bis(methylthio)methylene]glycine methyl ester, Boc-allyl-Gly-OH (dicyclohexylammonium) salt, Boc-D-Chg-OH, Boc-Chg-OH, (R)-N-Boc-(2'-chlorophenyl)glycine, Boc-L-cyclopropylglycine, (R)-N-Boc-4-fluorophenylglycine, 1. A composition selected from the group consisting of Boc-D-propargylglycine, Boc-(S)-3-thienylglycine, Boc-(R)-3-thienylglycine, D-α-cyclohexylglycine, L-α-cyclopropylglycine, N-(2-fluorophenyl)-N-(methylsulfonyl)glycine, N-(4-fluorophenyl)-N-(methylsulfonyl)glycine, Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH, N-(2-furoyl)glycine, L-α-neopentylglycine, D-propargylglycine, sarcosine, Z-α-phosphonoglycine trimethyl ester, and mixtures thereof.

2. 2. The composition of claim 1, wherein said glycine or a functional derivative thereof and said N-acetylcysteine ​​are provided to said individual orally.

3. The composition of claim 1 , wherein the glycine and the N-acetylcysteine ​​are comprised in a dipeptide.

4. The composition of claim 3 , wherein the dipeptide comprises N-acetylcysteinylglycine or cysteinylglycine.

Images